Women's Health Phase 3 Deal Benchmarks — US Only

Understanding Women's Health Deal Benchmarks at Phase 3

Phase 3 Women's Health licensing deals in US Only territory command a median upfront payment of $475M, with values ranging from $294M at the low end to $700M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the women's health therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $1.3B to $2.3B, with a median of $1.8B. Royalty rates for women's health assets at this stage typically fall between 9.4% and 17% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.

The US Only territory applies a 0.55x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating us only rights should calibrate upfront expectations and milestone structures accordingly.